UY25089A1 - NON-WATER VACCINES - Google Patents

NON-WATER VACCINES

Info

Publication number
UY25089A1
UY25089A1 UY25089A UY25089A UY25089A1 UY 25089 A1 UY25089 A1 UY 25089A1 UY 25089 A UY25089 A UY 25089A UY 25089 A UY25089 A UY 25089A UY 25089 A1 UY25089 A1 UY 25089A1
Authority
UY
Uruguay
Prior art keywords
solvent
polar
group
nonaqueous
immunogenic polypeptide
Prior art date
Application number
UY25089A
Other languages
Spanish (es)
Inventor
Hungerford James
Albrecht Mark
Original Assignee
Hoechst Roussel Vet Gmbh
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO7792A external-priority patent/AUPO779297A0/en
Priority claimed from AUPO7791A external-priority patent/AUPO779197A0/en
Application filed by Hoechst Roussel Vet Gmbh, Biotech Australia Pty Ltd filed Critical Hoechst Roussel Vet Gmbh
Publication of UY25089A1 publication Critical patent/UY25089A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulación de vacuna no acuosa de fase única que contiene un polipéptido inmunogénico disuelto en un solvente polar no acuoso. La formulación también puede contener adyuvantes y/o composiciones farmacéuticas que puedan administrarse conjuntamente con el polipéptido inmunogénico. Se relevan métodos para preparar dicha formulación de vacuna y se proporcionan métodos para utilizar las formulaciones a fin de prevenir y tratar enfermedades de mamíferos. El polipéptido inmunogénico proviene de un organismo parásito, preferentemente de un organismo seleccionado del grupo compuesto por los nematodos y los insectos. En una realización preferida, el solvente no acuoso comprende dimetilsulfóxido (DMSO),si bien pueden utilizarse también otros solventes polares no acuosos. En su forma más conveniente, el DMSO comprende de hasta un 6% de solvente no acuoso, y el resto comprende un solvente hidroxílico polar. El solvente hidroxílico polar se selecciona del grupo integrado por el glicerol formol y el propilén glicol, ó una mezcla de los mismos. En particular, las formulaciones de la presente invención pueden almacenarse durante períodos prolongados a temperaturas ambientes de hasta 40sC aproximadamente sin perder eficacia, es decir, la capacidad de inducir una respuesta inmune protectora. La presente invención es particularmente útil para la administración conjunta de sustancias farmacéuticas que son inestables en solución acuosa, como ser un compuesto antihelmíntico y de manera más preferida es una lactona marcocíclica del grupo de compuestos integrados por la avermectina y la milbemicina.A single phase nonaqueous vaccine formulation containing an immunogenic polypeptide dissolved in a nonaqueous polar solvent. The formulation may also contain adjuvants and / or pharmaceutical compositions that can be co-administered with the immunogenic polypeptide. Methods of preparing such a vaccine formulation are discussed and methods of using the formulations to prevent and treat mammalian diseases are provided. The immunogenic polypeptide comes from a parasitic organism, preferably from an organism selected from the group consisting of nematodes and insects. In a preferred embodiment, the nonaqueous solvent comprises dimethylsulfoxide (DMSO), although other non-aqueous polar solvents can also be used. In its most convenient form, DMSO comprises up to 6% non-aqueous solvent, and the remainder comprises a polar hydroxylic solvent. The polar hydroxylic solvent is selected from the group consisting of glycerol formaldehyde and propylene glycol, or a mixture thereof. In particular, the formulations of the present invention can be stored for prolonged periods at ambient temperatures of up to about 40sC without losing efficacy, i.e., the ability to induce a protective immune response. The present invention is particularly useful for the co-administration of pharmaceutical substances that are unstable in aqueous solution, such as being an anthelmintic compound and more preferably it is a framework cyclic lactone from the group of compounds composed of avermectin and milbemycin.

UY25089A 1997-07-10 1998-07-10 NON-WATER VACCINES UY25089A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO7792A AUPO779297A0 (en) 1997-07-10 1997-07-10 Novel vaccines
AUPO7791A AUPO779197A0 (en) 1997-07-10 1997-07-10 Novel vaccines

Publications (1)

Publication Number Publication Date
UY25089A1 true UY25089A1 (en) 2000-08-21

Family

ID=25645460

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25089A UY25089A1 (en) 1997-07-10 1998-07-10 NON-WATER VACCINES

Country Status (3)

Country Link
AR (1) AR013202A1 (en)
UY (1) UY25089A1 (en)
WO (1) WO1999002182A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27412A1 (en) * 2002-08-12 2003-06-30 Carlson Internat Inc A NEW PRODUCT FOR TICKET FIGHTING AND THE PREPAACINN PROCESS.
CA2769221A1 (en) * 2009-08-04 2011-02-10 Genentech, Inc. Concentrated polypeptide formulations with reduced viscosity
US9101557B2 (en) 2011-04-13 2015-08-11 Auburn University Combination of protein forms for hornfly vaccination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711602A (en) * 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
NZ210505A (en) * 1983-12-22 1988-06-30 Merck & Co Inc Parasiticidal compositions containing avermectin or milbemycin derivatives
US4853372A (en) * 1983-12-22 1989-08-01 Merck & Co., Inc. Non-aqueous ivermectin formulation with improved antiparasitic activity
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
DE69619894T2 (en) * 1995-06-30 2002-11-14 American Cyanamid Co., Madison Stable macrolides and macrolide vaccine compositions

Also Published As

Publication number Publication date
WO1999002182A3 (en) 1999-04-01
AR013202A1 (en) 2000-12-13
WO1999002182A2 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
ES2174027T3 (en) STABLE COMPOSITIONS CONTAINING MACROLIDES AND MACROLIDES COMBINED WITH VACCINES.
ES2620413T3 (en) Topical anthelmintic veterinary formulations
ES2184079T3 (en) AGENTS FOR THE FIGHT AGAINST INSECTS AND PARASITANT ACAROS IN HUMAN BEINGS.
ES2142798T3 (en) DERIVATIVES OF 3-AMIDO PIRAZOL, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
DK1158959T3 (en) Compositions and Methods for Improved Administration of Hydrophobic Therapeutic Agents
AR037490A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES
CY1114631T1 (en) PHARMACEUTICAL FORMS OF ECHINOCANDIN Containing surfactants that form a micelle
MX9304627A (en) COMPOSITIONS OF CRYSTALLINE AMIFOSTINE AND METHODS FOR THE PREPARATION AND USE OF THE SAME.
ATE398997T1 (en) SELF-NANOEMULSIFIING OILY FORMULATION FOR ADMINISTRATION OF POORLY WATER-SOLUBLE MEDICINAL PRODUCTS
CY1111413T1 (en) FREE FROM ZINC AND WINE IN ZINC INSULIN PREPARATIONS WITH IMPROVED STABILITY
BR9814229A (en) Cosmetic makeup
HN2003000184A (en) ACID INSULIN PREPARATIONS WITH IMPROVED STABILITY
ES2233566T3 (en) PROLONGED RELEASE COMPOSITIONS FOR THE PARENTERAL ADMINSITRATION OF MACROLITES.
PT1206189E (en) FORMULATIONS FOR ROTAVIRUS VACCINES
CL2004001255A1 (en) HERBICIDE LIQUID FORMULATION CONTAINING (A) ONE OR MORE DERIVATIVES OF POLYCARBOXYL ACIDS AND (B) ONE OR MORE INHIBITING ACTIVE COMPOUNDS OF ALS, PROCEDURE TO PREPARE FORMULATION THAT INCLUDES MIXING OF COMPONENTS AND METHOD P
PE20040324A1 (en) LIQUID LIQUID FORMULATIONS OF ENTECAVIR AND USE
ES2205926T3 (en) PRODUCTIVE METHOD OF INACTIVE VACCINES ASSOCIATED WITH AN EMULSION OF WATER IN ADJUTIVE OIL.
DK0525307T3 (en) Stable preparations for parenteral administration and their use
UY25089A1 (en) NON-WATER VACCINES
PE20220593A1 (en) MACITENTAN COMPRESSED COMPOSITIONS, METHODS AND USES THEREOF
AR037138A1 (en) PHARMACEUTICAL FORMULATION, USE OF FULVESTRANT IN THE PREPARATION OF THE SAME AND STERILE SYRINGE OR ROAD THAT INCLUDE SUCH FORMULATION
ES2204958T3 (en) LONG-EFFECT OXITETRACICLINE COMPOUND.
TR200302027T4 (en) Drug compositions for the treatment of parasitic diseases in animals
ES2040774T3 (en) PROCEDURE FOR THE PREPARATION OF A DRUG FORMULATION.
ES2059471T3 (en) A PROCEDURE FOR PREPARING A RODAMINE DERIVATIVE.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20121206